Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Change in Taxes (2023 - 2024)

Spero Therapeutics (SPRO) has disclosed Change in Taxes for 2 consecutive years, with $77000.0 as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Change in Taxes rose 104.22% year-over-year to $77000.0, compared with a TTM value of -$2.0 million through Sep 2025, changed N/A, and an annual FY2024 reading of -$213000.0, down 155.04% over the prior year.
  • Change in Taxes was $77000.0 for Q4 2024 at Spero Therapeutics, up from -$290000.0 in the prior quarter.
  • Across five years, Change in Taxes topped out at $77000.0 in Q4 2024 and bottomed at -$1.8 million in Q4 2023.